{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    13,
    16,
    20,
    21,
    32,
    33,
    37,
    38,
    55
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Inclusion and Exclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1 and 5.2",
        "sectionTitle": "Inclusion Criteria and Exclusion Criteria",
        "description": "Reference to inclusion and exclusion criteria for risk minimization measures"
      },
      {
        "id": "ref_2",
        "name": "Laboratory Monitoring Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.4",
        "sectionTitle": "Clinical Safety Laboratory Tests",
        "description": "Reference to biochemical and hematology laboratory monitoring"
      },
      {
        "id": "ref_3",
        "name": "Vital Signs Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.2",
        "sectionTitle": "Vital Signs",
        "description": "Reference to observation of vital signs"
      },
      {
        "id": "ref_4",
        "name": "ECG Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.3",
        "sectionTitle": "Electrocardiograms",
        "description": "Reference to observation of ECGs"
      },
      {
        "id": "ref_5",
        "name": "Holter ECG Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.4.3",
        "sectionTitle": "Electrocardiograms",
        "description": "Reference to detailed information on Holter ECGs"
      },
      {
        "id": "ref_6",
        "name": "Prohibited Medicines Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference to prohibited medicines at study entry indicated in exclusion criteria"
      },
      {
        "id": "ref_7",
        "name": "Blinding Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.3.2 and 6.3.3",
        "sectionTitle": "Blinding and Emergency Unblinding",
        "description": "Reference to blinding procedures for laboratory results"
      },
      {
        "id": "ref_8",
        "name": "AE Definition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Adverse Events: Definitions and Procedures",
        "description": "Reference to definitions of AE and SAE"
      },
      {
        "id": "ref_9",
        "name": "SAE Follow-up Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.2",
        "sectionTitle": "Follow-up of Adverse Events and Serious Adverse Events",
        "description": "Reference to follow-up procedures for AEs"
      },
      {
        "id": "ref_10",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to SoA for AE and SAE collection timepoints"
      },
      {
        "id": "ref_11",
        "name": "Contraception Requirements Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "Contraception and Barrier Requirements",
        "description": "Reference to definition of woman of childbearing potential"
      },
      {
        "id": "ref_12",
        "name": "Informed Consent Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Study Governance",
        "description": "Reference to informed consent requirements"
      },
      {
        "id": "ref_13",
        "name": "Clinical Laboratory Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference to list of clinical laboratory tests"
      },
      {
        "id": "ref_14",
        "name": "Study Termination Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Study Governance",
        "description": "Reference to general information on study termination"
      },
      {
        "id": "ref_15",
        "name": "Liver Safety Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Liver Safety: Suggested Actions and Follow-up Assessments",
        "description": "Reference to liver safety actions and assessments"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Study to include approx. 30% or more of each sex",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.1 Inclusion Criteria",
        "pageNumber": 22
      },
      {
        "id": "annot_2",
        "text": "Confidential - This document is the property of Merck KGaA, Darmstadt, Germany, or one of its subsidiaries. It is intended for restricted use only and may not – in full or part – be passed on, reproduced, published or used without express permission of Merck KGaA, Darmstadt, Germany, or its subsidiary.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Protocol Amendment Summary",
        "pageNumber": 3
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-12-01",
        "description": "Non-substantial protocol amendment to allow rescreening of participants and change wording of inclusion criteria for flexibility regarding ratio of sexes"
      },
      {
        "id": "ver_2",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-10-24",
        "description": "Updated Protocol"
      },
      {
        "id": "ver_3",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-08-29",
        "description": "Original Protocol"
      }
    ],
    "summary": {
      "referenceCount": 15,
      "annotationCount": 2,
      "versionCount": 3
    }
  }
}